Consensus document and recommendations on the use of natriuretic peptides in clinical practice

Abstract Natriuretic peptides are a useful laboratory tool for the diagnosis, prognosis and treatment of patients with heart failure. Natriuretic peptides are used in various healthcare settings (consultations, emergency department, hospitalization, laboratory) and by various primary care and specialized professionals. However, their use in clinical practice is still scare and uneven. Properly using and interpreting natriuretic peptides in clinical practice requires a minimum of prelaboratory (pathophysiology), laboratory (methods) and postlaboratory (interpretation and integration of clinical data) expertise. The objective of this consensus document, developed by several scientific societies, is to update the necessary concepts and expertise on natriuretic peptides that enable its application in the diagnosis, prognosis and treatment of heart failure, in various healthcare environments.

[1]  R. Doughty,et al.  Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. , 2003, Journal of the American College of Cardiology.

[2]  D. Goeddel,et al.  Molecular Biology of the Natriuretic Peptides and Their Receptors , 1992, Circulation.

[3]  P. Hildebrandt,et al.  Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. , 2006, European heart journal.

[4]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[5]  F. Maupas-Schwalm,et al.  Head-to-head comparison of 10 natriuretic peptide assays , 2015, Clinical chemistry and laboratory medicine.

[6]  M. Chávarri,et al.  Usefulness of NTproBNP in the Emergency Management of Patients With Severe Dyspnea and an Uncertain Heart Failure Diagnosis , 2005 .

[7]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[8]  C. Camargo,et al.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.

[9]  Diederick E Grobbee,et al.  Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis , 2011, Heart.

[10]  V. Hasselblad,et al.  Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. , 2009, American heart journal.

[11]  K. Dickstein,et al.  [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]. , 2005, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[12]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[13]  A. Bayés-Genís.  NTproBNP circulante, un nuevo biomarcador para el diagnóstico del paciente con disnea aguda , 2005 .

[14]  J. Januzzi,et al.  Amino-terminal pro-B-type natriuretic peptide testing and prognosis in patients with acute dyspnea, including those with acute heart failure. , 2008, The American journal of cardiology.

[15]  C. Schindler,et al.  Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. , 2006, Archives of internal medicine.

[16]  Shawn A. Gregory,et al.  Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. , 2011, Journal of the American College of Cardiology.

[17]  Katharina Dworzynski,et al.  The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting , 2015, BMJ : British Medical Journal.

[18]  Juan Cinca,et al.  Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. , 2008, European heart journal.

[19]  B. Billah,et al.  B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. , 2010, Archives of internal medicine.

[20]  Antoni Bayes-Genis,et al.  NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. , 2006, European heart journal.

[21]  J. Hollander,et al.  B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure: Analysis From Breathing Not Properly (BNP) Multinational Study , 2002, Circulation.

[22]  Ahmed M Bayoumi,et al.  Improving the diagnosis of acute heart failure using a validated prediction model. , 2009, Journal of the American College of Cardiology.

[23]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[24]  P. Collinson,et al.  Amino-terminal pro-B-type natriuretic peptide: analytic considerations. , 2008, The American journal of cardiology.

[25]  K. Swedberg,et al.  Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.

[26]  M. V. Chávarri,et al.  Utilidad del NTproBNP en el manejo urgente del paciente con disnea severa y diagnóstico dudoso de insuficiencia cardíaca , 2005 .

[27]  N-Terminal Pro–B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure: Primary Results of the Canadian Prospective Randomized Multicenter IMPROVE-CHF Study , 2007 .

[28]  R. Latini,et al.  Amino-terminal pro-B-type natriuretic peptides and prognosis in chronic heart failure. , 2008, The American journal of cardiology.

[29]  Kent B Lewandrowski,et al.  Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea. , 2008, Archives of internal medicine.

[30]  Richard Kamin,et al.  Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. , 2003, Journal of the American College of Cardiology.

[31]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[32]  A. Ferreira,et al.  N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.

[33]  C. Camargo,et al.  Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. , 2006, Archives of internal medicine.

[34]  M. Cowie,et al.  The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: Results of the UK natriuretic peptide study , 2005, European journal of heart failure.

[35]  Mario Plebani,et al.  Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. , 2012, European heart journal.